ClinicalTrials.gg
CompletedNCT03371082GLITTER1Updated May 14, 2024Results posted

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

A Phase 3 interventional study of Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 1, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 85 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
39th of 1,242
576 · median 40
Started
2017
with 75 others
Phase 3
147 of 1,458
10 open now
Registered
812th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 39th largest by enrollment of the 1,242 interventional ones that give a count, is one of 76 that started in 2017, is one of 147 in phase 3, and was the 812th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

•To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity

Secondary Objective:

Immunogenicity:

  • To evaluate the percentage of subjects with negative anti-insulin antibodies (AIAs) at baseline who develop confirmed positive AIA up to Week 26, the percentage of baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and percentage of subjects who develop confirmed positive AIA up to visit Week 26 of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

Safety:

•To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

Efficacy:

•To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Diabetes
  • Diabetes Type 1
  • Type 1
  • Basal
  • Insulin
  • Glargine
  • T1DM
  • Diabetes Mellitus
  • Insulin Dependent Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or nonpregnant, nonlactating female subjects between the ages of 18 and 75 years, inclusive.
  2. Ability to provide written, personally signed, and dated to participate in the study, in accordance with the ICH GCP Guideline E6 and all applicable regulations, before initiating any study-related procedures.
  3. Ability to understand and fully comply with all study procedures and restrictions.
  4. Subjects with a confirmed diagnosis of type 1 diabetes mellitus who have been on an approved basal and bolus insulin regimen for at least 6 months (the type or brand of insulin should not have changed in the 6 months before screening).
  5. ≤ 11.0%.
  6. ≥ 19 kg/m2 and ≤ 35 kg/m2.
  7. Adherence to a prudent diet and exercise regimen recommended by the medical provider, and willingness to maintain these consistently for the duration of the study.
  8. Concomitant medications are allowed, provided that no significant dosing changes are anticipated during the study (see the exclusion criteria below for specific prohibited concomitant medications); for concomitant thyroid medications, subjects must have been on a stable dosage for 90 days before screening.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical study or use of any study drug within 30 days before screening.
  2. Previous use of a biosimilar insulin, either basal or bolus.
  3. Diabetic ketoacidosis within a year before screening.
  4. Brittle type 1 diabetes mellitus within the year before screening (e.g., multiple hospitalizations related to diabetes mellitus and/or severe hypoglycemia for which the subject required 3rd party assistance).
  5. Any severe, delayed sequela of diabetes mellitus, e.g., worsening end-stage renal disease, advanced coronary artery disease, or myocardial infarction within the year before screening, or autonomic peristaltic problems, e.g., gastroparesis.
  6. Anticipated change in insulin used during the study (change in dosage is allowed, but change in type or brand of insulin will result in the subject being withdrawn from the study).
  7. Inadequately controlled thyroid disease, defined as a TSH or free T4 value > the .
  8. \< 19 kg/m2 or > 35 kg/m2.
  9. Any (in the opinion of the Investigator) hematology or chemistry test results at screening, including any liver function test > 3x the upper limit of normal (subjects with elevated due to Gilbert syndrome are eligible to participate).
  10. Documented history of anti-insulin antibodies.
  11. Treatment with glucocorticosteroids, , or cytostatic agents within 60 days before screening (newly-prescribed or high-dose are prohibited; chronically administered oral, inhaled, topical, or intra-articular corticosteroids at a stable dosage are allowed if no increase in dose is anticipated during the study; See Appendix 3 [Section 17.3] for a list of allowed and prohibited medications).
  12. Current use of medication intended to cause weight loss or weight gain.
  13. Alcohol or substance use disorder within the 2 years before screening.
  14. Any previous or anticipated treatment with interferons.
  15. Any history of malignant disease within 5 years before screening, except for adequately treated basal cell carcinoma.
  16. Severe concomitant physical or psychiatric diseases or conditions
  17. A history of a positive test result for , , or ; any subject who has a positive test result during the study may continue at the discretion of the Investigator.
  18. Any history of pancreatitis or pancreatectomy.
  19. Any diagnosis or condition that requires the subject to undergo procedures that could decrease antibodies in plasma or that would require treatment with immunosuppressant agents.
  20. Any condition e.g., splenectomy, disease, or rheumatologic disease, that could affect immunologic responses, could indicate an altered immune system, or could require treatment with a prohibited medication.
  21. Any unresolved infection or a history of active infection within 30 days before screening other than mild or viral illness (as judged by the Investigator).
  22. Any other disease or condition that in the opinion of the Investigator could confound the study results or limit the subject's ability to participate in the study or comply with follow-up procedures; or any other factor that would indicate a significant risk of loss to follow up.
  23. Intolerance or history of to insulin glargine or any of IP.
  24. Inability or unwillingness to wear the CGM sensor as required for the study, or to comply with the concomitant medication requirements in the FreeStyle Libre Pro Indications and Important Safety Information, during the CGM periods.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
576 participants (actual)

Study arms

  • Experimental
    Gan & Lee Insulin Glargine Injection

    Gan \& Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insulin Glargine Injection group will participate in the study for 26 weeks.

    Biological: Gan & Lee Insulin Glargine Injection

  • Active comparator
    Lantus®

    Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.

    Biological: Lantus®

Interventions

  • BiologicalGan & Lee Insulin Glargine Injection

    Route of administration: subcutaneous injection

  • BiologicalLantus®

    Route of administration: subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Treatment-induced Anti-Insulin Antibody (TI-AIA)

    TI-AIA is the Composite of Newly Confirmed Positive AIA or Important-Increase in AIA titer

    Time frame: Assessed up to Week 26

Secondary outcomes

  1. Glycosylated Hemoglobin HbA1c

    The change between baseline (CFB) in HbA1c and at 26 weeks

    Time frame: Assessed up to Week 26

  2. Number of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline

    The number of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.

    Time frame: Assessed up to Week 26

  3. Number of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline.

    The number of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to 26 weeks.

    Time frame: Up to Week 26

  4. Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline

    The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.

    Time frame: Assessed up to Week 26

  5. Number of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline.

    The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin neutralizing antibodies after baseline and up to visit Week 26.

    Time frame: Up to Week 26

  6. Number of Subjects With Confirmed Positive AIA After Baseline.

    The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.

    Time frame: Up to Week 26

  7. Postbaseline FBG Control

    The number of subjects who achieve an FBG test result of ≤ 6.0 mmol/L at visit Week 26.

    Time frame: Up to Week 26

  8. HbA1c Control.

    The number of subjects who achieve a HbA1c of \< 7.0% at visit Week 26.

    Time frame: Up to Week 26

07

Results

Posted May 14, 2024

Participant flow

Reviewed and approved by each IRB.

Participant flow — Overall Study
MilestoneGan & Lee Insulin Glargine InjectionLantus®
Started287289
Completed258255
Not completed2934

Outcome measures

PrimaryTreatment-induced Anti-Insulin Antibody (TI-AIA)

TI-AIA is the Composite of Newly Confirmed Positive AIA or Important-Increase in AIA titer

Time frame:
Assessed up to Week 26
Reported as:
Mean · Titers
Treatment-induced Anti-Insulin Antibody (TI-AIA)
TitersGan & Lee Insulin Glargine InjectionLantus®
Treatment-induced Anti-Insulin Antibody (TI-AIA)4.8 ± 88.8842.5 ± 332.90
Statistical analysis
  • Gan & Lee Insulin Glargine Injection vs Lantus® · Risk difference (rd): 0.6 · 90% CI -5.4 to 6.5The asymptotic standard error was planned and is reported above.
SecondaryGlycosylated Hemoglobin HbA1c

The change between baseline (CFB) in HbA1c and at 26 weeks

Time frame:
Assessed up to Week 26
Reported as:
Least squares mean · Percent of total hemoglobin
Glycosylated Hemoglobin HbA1c
Percent of total hemoglobinGan & Lee Insulin Glargine InjectionLantus®
Glycosylated Hemoglobin HbA1c-0.08 ± 0.0720.00 ± 0.061
SecondaryNumber of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline

The number of subjects in each treatment group with negative AIA at baseline who develop confirmed positive AIA after baseline and up to visit Week 26.

Time frame:
Assessed up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Number of Subjects in Each Treatment Group With Negative AIA at Baseline Who Develop Confirmed Positive AIA After Baseline6359
SecondaryNumber of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline.

The number of subjects in each treatment group with confirmed positive AIA at baseline and at least a 4-fold increase in titers after baseline and up to 26 weeks.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline.
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Number of Subjects in Each Treatment Group With Confirmed Positive AIA at Baseline and at Least a 4-fold Increase in Titers After Baseline.1114
SecondaryMean Change From Baseline in Each Treatment Group in AIA Titers After Baseline

The mean change from baseline in each treatment group in AIA titers after baseline and up to visit Week 26.

Time frame:
Assessed up to Week 26
Reported as:
Mean · Titers
Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline
TitersGan & Lee Insulin Glargine InjectionLantus®
Mean Change From Baseline in Each Treatment Group in AIA Titers After Baseline4.8 ± 88.88-42.5 ± 332.90
SecondaryNumber of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline.

The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26 who develop any anti-insulin neutralizing antibodies after baseline and up to visit Week 26.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline.
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Number of Subjects With Confirmed Positive AIA After Baseline Who Develop Any Anti-insulin Neutralizing Antibodies After Baseline.1316
SecondaryNumber of Subjects With Confirmed Positive AIA After Baseline.

The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed Positive AIA After Baseline.
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Number of Subjects With Confirmed Positive AIA After Baseline.102103
SecondaryPostbaseline FBG Control

The number of subjects who achieve an FBG test result of ≤ 6.0 mmol/L at visit Week 26.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Postbaseline FBG Control
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Lack of Postbaseline FBG control248247
Sufficient Postbaseline FBG control3942
SecondaryHbA1c Control.

The number of subjects who achieve a HbA1c of \< 7.0% at visit Week 26.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
HbA1c Control.
ParticipantsGan & Lee Insulin Glargine InjectionLantus®
Lack of Postbaseline HbA1c Control241245
Sufficient Postbaseline HbA1c Control4644

Adverse events

Collected over 26-weeks. Non-serious events are listed at a 0.3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gan & Lee Insulin Glargine Injection0/287 (0%)10/287 (3.5%)160/287 (55.7%)
Lantus®1/289 (0.3%)14/289 (4.8%)161/289 (55.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventGan & Lee Insulin Glargine InjectionLantus®
HypoglycemiaMetabolism and nutrition disorders3/2871/289
Acute kidney injuryRenal and urinary disorders0/2872/289
DepressionPsychiatric disorders0/2872/289
Benign neoplasm of spinal cordMusculoskeletal and connective tissue disorders1/2870/289
Carotid artery occlusionBlood and lymphatic system disorders1/2870/289
CellulitisSkin and subcutaneous tissue disorders1/2870/289
Diabetic footMetabolism and nutrition disorders1/2870/289
GangreneInfections and infestations1/2870/289
Lower limb fractureMusculoskeletal and connective tissue disorders1/2870/289
Post procedural infectionGeneral disorders1/2870/289
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGan & Lee Insulin Glargine InjectionLantus®
HypoglycemiaMetabolism and nutrition disorders158/287161/289
Weight increaseInvestigations3/2871/289
FatigueGeneral disorders3/2870/289
HyperglycemiaMetabolism and nutrition disorders2/2871/289
Blood creatine phosphokinase increasedMetabolism and nutrition disorders1/2870/289
Diabetes mellitusMetabolism and nutrition disorders1/2870/289
DizzinessNervous system disorders1/2870/289
Face oedemaSkin and subcutaneous tissue disorders1/2870/289
Foot FractureMusculoskeletal and connective tissue disorders1/2870/289
Herpes zosterSkin and subcutaneous tissue disorders1/2870/289

Baseline characteristics

All Subjects Assigned randomly to treatment (full analysis set).

Age, Categorical
Age, Categorical(Participants)Gan & Lee Insulin Glargine InjectionLantus®Total
<=18 years000
Between 18 and 65 years256252508
>=65 years313768
Age, Continuous
Age, Continuous(Years)Gan & Lee Insulin Glargine InjectionLantus®Total
Mean45.7 ± 13.9646.7 ± 14.4646.2 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Gan & Lee Insulin Glargine InjectionLantus®Total
Female103112215
Male184177361
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gan & Lee Insulin Glargine InjectionLantus®Total
Hispanic or Latino231639
Not Hispanic or Latino259272531
Unknown or Not Reported516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gan & Lee Insulin Glargine InjectionLantus®Total
American Indian or Alaska Native011
Asian6713
Native Hawaiian or Other Pacific Islander202
Black or African American131427
White262265527
More than one race213
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Gan & Lee Insulin Glargine InjectionLantus®Total
Hungary202141
United States151150301
Czechia242549
Poland373774
Germany292857
Spain262854
Anti-Insulin Antibodies (AIA)
Anti-Insulin Antibodies (AIA)(Participants)Gan & Lee Insulin Glargine InjectionLantus®Total
Negative236239475
Positive494897
Nonreportable022
Missing202
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Gan & Lee Insulin Glargine InjectionLantus®Total
Mean27.01 ± 3.87527.11 ± 4.23727.06 ± 4.058

5 further baseline measures are reported on the registry.

08

Study locations

85 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Valley Research
    Fresno, California 93720, United States
  • The Rose Salter Medical Research Foundation
    Newport Beach, California 92663-3303, United States
  • California Medical Research Association
    Northridge, California 91324, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Meridien Research
    Bradenton, Florida 34201, United States
  • The Center for Diabetes and Endocrine Care
    Fort Lauderdale, Florida 33312, United States
  • Homestead Associates in Research
    Homestead, Florida 33032, United States
  • Central Florida Endocrine and Diabetes Consultants - Maitland
    Maitland, Florida 32751, United States
  • Biotech Pharmaceutical Group, LLC
    Miami, Florida 33155, United States
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • Miami Dade Medical Research Institute, LLC
    Miami, Florida 33176, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Peninsula Research
    Ormond Beach, Florida 32174, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Sestron Clinical Research
    Marietta, Georgia 30060, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Advanced Clinical Research - Idaho
    Meridian, Idaho 83642, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • John H. Stroger Jr. Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Midwest CRC
    Crystal Lake, Illinois 60012, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Kentucky Diabetes Endocrinology Center
    Lexington, Kentucky 40503-1473, United States
  • Palm Research Center, Inc.
    Las Vegas, Nevada 89148, United States
  • Physicians East - Greenville
    Greenville, North Carolina 27834, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Endocrinology Reserach Associates, Inc.
    Columbus, Ohio 43201, United States
  • Aventiv Research, Inc.
    Columbus, Ohio 43213-6523, United States
  • PriMed Clinical Research
    Dayton, Ohio 45419, United States
  • University Diabetes & Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • ClinSearch - Clinical Research Specialists
    Chattanooga, Tennessee 37421, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • Texas Diabetes & Endocrinology - Central Austin
    Austin, Texas 78731-4309, United States
  • Texas Diabetes & Endocrinology - South Austin
    Austin, Texas 78749, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Texas Diabetes & Endocrinology - Round Rock
    Round Rock, Texas 78681, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Northeast Clinical Research of San Antonio
    Schertz, Texas 78154, United States
  • Radiant Research
    Murray, Utah 84123, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • Burke Internal Medicine & Research
    Burke, Virginia 22105, United States
  • Stonesifer Clinical Research
    Federal Way, Washington 98003, United States
  • Rainier Clinical Research Center, Inc.
    Renton, Washington 98057, United States
  • MultiCare Health System Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Diabetologie České Budějovice s.r.o
    České Budějovice, Jihocesky KRAJ 370 01, Czechia
  • Krajská zdravotní, a.s., Masarykova nemocnice v Ústí nad Labem
    Ústí Nad Labem, Severoceský KRAJ 401 13, Czechia
  • Diahaza s.r.o.
    Holešov, 769 01, Czechia
  • StefaMed
    Hradec Králové, 503 41, Czechia
  • Diabetologie MUDr. Tomáš Edelsberger
    Krnov, 794 01, Czechia
  • PreventaMed
    Olomouc, 779 00, Czechia
  • Genom s.r.o
    Ostrava, 709 00, Czechia
  • Studienzentrum Aschaffenburg
    Aschaffenburg, Bayern 63739, Germany
  • Diabetes-falkensee.de
    Falkensee, Brandenburg 14612, Germany
  • Gemeinschaftspraxis Diabeteszentrum Dortmund
    Dortmund, Nordrhein-westfalen 44137, Germany
  • Diabetes Schwerpunktpraxis, Gemeinschaftspraxis Alain Barakat und Helene Willems
    Duisburg, Nordrhein-westfalen 47051, Germany
  • Diabetologische Schwerpunktpraxis Pirna
    Pirna, Sachsen 01796, Germany
  • RED-Institut GmbH
    Oldenburg, Schleswig-holstein 23758, Germany
  • Lausmed Egeszsegugyi es Szolgaltato Kft.
    Baja, Bacs-kiskun 6500, Hungary
  • CRU Hungary Egészségügyi és Szolgáltató Kft.
    Miskolc, Borsod-abauj-zemplen 3529, Hungary
  • Markhot Ferenc Oktatókórház és Rendelointézet
    Eger, Heves 3300, Hungary
  • Zala County Hospital
    Zalaegerszeg, Zala H-8900, Hungary
  • Betegapolo-Irgalmasrend Budai Irgalmasrendi Kórház, Diabetológiai Ambulancia
    Budapest, 1023, Hungary
  • Synexus Magyarország
    Budapest, 1036, Hungary
  • Semmelweis Egyetem II. Sz. Belgyógyászati Klinika
    Budapest, 1088, Hungary
  • KO-MED Centra Kliniczne Lublin - Królewska
    Lublin, Lubelskie 20-109, Poland
  • Pratia MCM Kraków
    Kraków, Malopolskie 30-510, Poland
  • NZOZ Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne "Diab-Endo-Met"
    Kraków, Malopolskie 31-261, Poland
  • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie
    Warszawa, Mazowieckie 02-507, Poland
  • Centrum Badań Klinicznych PI-House
    Gdansk, Pomorskie 80-546, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Gdanska Poradnia Cukrzycowa
    Gdansk, Pomorskie 80-858, Poland
  • Praktyka Lekarska Ewa Krzyzagórska
    Poznań, Wielkopolskie 61-655, Poland
  • Hospital Universitari de Girona Doctor Josep Trueta
    Girona, Gerona 17007, Spain
  • Complejo Hospitalario Universitario de Ferrol
    Ferrol, LA Coruna 15405, Spain
  • Centro de Especialidades San Jose Obrero. Hospital Universitario Virgen de la Victoria
    Málaga, Malaga 29006, Spain
  • Complejo Hospitalario Universitario La Coruña
    La Coruna, 15006, Spain
  • Hospital Universitario Ramón Y Cajal
    Madrid, 28034, Spain
  • Nuevas Tecnologías en Diabetes y Endocrinología
    Sevilla, 41003, Spain
  • Hospital Universitario Nuestra Señora de Valme
    Sevilla, 41014, Spain
  • Consorci Hospital General Universitari de València
    Valencia, 46014, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Aug 2019, 21 months.

Results were first posted in May 2024, 4 years 8 months after primary completion. A results delay was requested in Jul 2020.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Dec 13, 2017
StartActual
Oct 31, 2017
Primary completionActual
Aug 19, 2019
CompletionActual
Aug 19, 2019
Results delay requested
Jul 7, 2020
Results first posted
May 14, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03371082
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Oct 31, 2017
Primary completion
Aug 19, 2019
Completion
Aug 19, 2019
Results posted
May 14, 2024
Last update
May 14, 2024

Study contacts

Jia Lu, MD, PhD
study director · Gan & Lee Pharmaceuticals, USA
Elena A. Christofides, MD,FACE
principal investigator · Endocrinology Research Associates, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion